Medtronic patent award
This article was originally published in The Gray Sheet
Executive SummaryAGA Medical must pay Medtronic $57 million in past damages and an 11% royalty on future U.S. sales of its Amplatzer Occluder and vascular plug product lines through 2018, following a San Francisco district court decision that the product lines infringe Medtronic's two "Jervis" patents, the firms said Aug. 6. AGA Medical plans to "vigorously defend" the case, and notes that a non-jury trial scheduled for later this year could alter the final outcome. Medtronic also has sued W.L. Gore, alleging infringement of the same patents
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.